Skip to main content
. 2013 Dec;347(3):755–764. doi: 10.1124/jpet.113.208959

Fig. 2.

Fig. 2.

(A) Steady-state plasma concentrations of sunitinib after a continuous intraperitoneal infusion at 30 µg/h for 48 hours in wild-type, Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)Bcrp1(−/−) mice. (B) Corresponding steady-state brain concentrations of sunitinib in wild-type, Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)Bcrp1(−/−) mice. (C) Steady-state brain-to-plasma ratios of sunitinib.